ArticleDiscover oncology2025
Proteomic analysis of Burkitt lymphoma tissues: insights into the impact of age and EBV infection on protein expression and molecular characteristics.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
We aim to investigate the molecular heterogeneity of Burkitt lymphoma (BL) by analyzing the impact of age and Epstein-Barr virus (EBV) infection on protein expression in tumor tissues. Using liquid chromatography-mass spectrometry (LC-MS), we performed proteomic analysis on 10 formalin-fixed paraffin-embedded (FFPE) BL tissue samples (5 adults, 5 pediatric; stratified by EBV status) alongside clinical data from 273 BL patients. Clinically, pediatric patients showed higher lactate dehydrogenase (LDH) levels and advanced tumor stages (P < 0.05), while EBV-positive cases exhibited unique metastatic potential. Key findings revealed significant age-related disparities: adult BL patients exhibited 343 differentially expressed proteins (208 up-regulated, 135 down-regulated) compared to pediatric cases, predominantly enriched in energy metabolism (e.g., PFKM, PGM2) and oxidative stress response pathways (e.g., SOD1, IDH1). EBV-positive BL demonstrated distinct molecular signatures, with 176 differentially expressed proteins (93 up-regulated, 83 down-regulated) linked to purine metabolism (e.g., IMPDH2), apoptosis (e.g., MAPK13, BID), autophagy pathway (e.g., ATG3) and cytoskeletal remodeling (e.g., ARHGAP9, SCRIB). Our results provide novel insights into BL pathogenesis, emphasizing the interplay of age and EBV in shaping molecular landscapes. This study underscores the need for multi-omics integration to advance precision therapy strategies for BL subtypes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.